Romain Teinturier

Oncofactory  is a science-driven company, part of the ERBC Group, offering biopharma companies a unique technology platform based on avian PDX (AVI-PDX™) known as a New Approach Methodology (NAM) for rapid assessment of therapeutic efficacy and in-depth characterization of mechanisms of action to evaluate therapeuticcompounds in oncology.

 While generating patient tumor replicas in avian embryos (AVI-PDX™) in combination with state-of-the-art 3D imaging and large-scale molecular analysis, ONCOFACTORY offer services to conduct proof of efficacy studies and assist clinical patient recruitment.

ONCOFACTORY gives access to in vivo models that are unmatched in speed (10 days), scientific robustness, predictivity and ethical compliance (3Rs).